Voyager Therapeutics (NASDAQ:VYGR) Share Price Breaks Below 50 Day Moving Average - Here's What Happened

Key Points

• Voyager Therapeutics shares fell below their 50-day moving average, dropping 7.3% to $2.27 after reaching an intraday low of $2.25, on trading volume of roughly 967,000 shares.
• Analyst sentiment remains mixed, but the stock carries a consensus “Moderate Buy” rating and a $16.50 target price; ratings range from Strong Buy to Sell.
• The company reported a quarterly loss of $0.40 per share, better than estimates, but revenue of $3.17 million missed expectations and profitability remained deeply negative.

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $3.08 and traded as low as $2.25. Voyager Therapeutics shares last traded at $2.27, with a volume of 967,005 shares trading hands.

Analysts Set New Price Targets

A number of brokerages recently commented on VYGR. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Voyager Therapeutics in a report on Friday. HC Wainwright reissued a "buy" rating on shares of Voyager Therapeutics in a report on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

Voyager Therapeutics Stock Down 7.3%

The company has a market capitalization of $139.88 million, a PE ratio of -1.26 and a beta of 1.28. The company's 50 day moving average is $3.08 and its two-hundred day moving average is $3.47.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.08. The company had revenue of $3.17 million for the quarter, compared to the consensus estimate of $4.52 million. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 57.92%. Analysts forecast that Voyager Therapeutics, Inc. will post -1.63 EPS for the current year.

Institutional Trading of Voyager Therapeutics

Hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new position in Voyager Therapeutics in the second quarter worth about $18,102,000. EcoR1 Capital LLC increased its stake in Voyager Therapeutics by 497.2% during the fourth quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company's stock worth $15,731,000 after acquiring an additional 3,332,544 shares during the last quarter. Altshuler Shaham Ltd bought a new stake in Voyager Therapeutics during the fourth quarter worth approximately $801,000. Renaissance Technologies LLC raised its position in Voyager Therapeutics by 95.0% during the first quarter. Renaissance Technologies LLC now owns 578,024 shares of the company's stock valued at $2,231,000 after purchasing an additional 281,574 shares during the period. Finally, Deutsche Bank AG purchased a new stake in Voyager Therapeutics during the second quarter valued at approximately $180,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company uses its proprietary TRACER capsid discovery platform to identify adeno-associated virus (AAV) capsids designed to improve the delivery of genetic medicines to the brain and central nervous system.

Voyager's research and development programs have addressed conditions including Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis and Friedreich's ataxia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.